High-intensity exercise as a treatment for Parkinson's disease
Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3
This study is looking at whether doing high-intensity endurance exercise can help people who have just been diagnosed with Parkinson's disease by slowing down their symptoms, and it's designed for those who want to explore new ways to manage their condition beyond medication.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10907607 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of high-intensity endurance exercise as a primary treatment for individuals recently diagnosed with Parkinson's disease. It aims to determine if this type of exercise can slow the progression of both motor and non-motor symptoms of the disease, which current medications do not adequately address. Participants will engage in structured exercise programs, focusing on maintaining high heart rates, and the study will assess the impact of this regimen over time. The research builds on previous findings that suggest exercise may provide significant benefits for those with Parkinson's.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently been diagnosed with Parkinson's disease and have not yet started dopaminergic medication.
Not a fit: Patients with advanced Parkinson's disease or those already on dopaminergic medications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a non-pharmacological approach to significantly improve the quality of life and functional abilities of patients with Parkinson's disease.
How similar studies have performed: Previous studies have shown promising results for exercise interventions in Parkinson's disease, indicating that this approach may be effective.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Corcos, Daniel M. — Northwestern University at Chicago
- Study coordinator: Corcos, Daniel M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.